These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

143 related articles for article (PubMed ID: 30214681)

  • 1. PKCι and YAP1 are crucial in promoting pancreatic tumorigenesis.
    Wang P; Wei D; Zhang H; Chen J; Zhang D; Ganapathy S; Isakson P; Chen C; Zhu T
    Oncotarget; 2018 Aug; 9(67):32736-32750. PubMed ID: 30214681
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Mu-KRAS attenuates Hippo signaling pathway through PKCι to sustain the growth of pancreatic cancer.
    Wang P; Zhang H; Yang J; Li Z; Wang Y; Leng X; Ganapathy S; Isakson P; Chen C; Zhu T
    J Cell Physiol; 2020 Jan; 235(1):408-420. PubMed ID: 31230347
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Transcription factor Sp1 is upregulated by PKCι to drive the expression of YAP1 during pancreatic carcinogenesis.
    Yang J; Wang J; Zhang H; Li C; Chen C; Zhu T
    Carcinogenesis; 2021 Apr; 42(3):344-356. PubMed ID: 33146712
    [TBL] [Abstract][Full Text] [Related]  

  • 4. PKCι regulates the expression of PDL1 through multiple pathways to modulate immune suppression of pancreatic cancer cells.
    Zhang H; Zhu Y; Wang J; Weng S; Zuo F; Li C; Zhu T
    Cell Signal; 2021 Oct; 86():110115. PubMed ID: 34375670
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [The Effects of PKCι on Anti-tumor Activity of Cytokine-induced Killer Cells Against Pancreatic Cancer Cells and the Possible Underlying Mechanisms].
    Zhang HM; Wang YR; Yang JH; Leng XH; Wang PP; Li ZX; Zhu TB
    Sichuan Da Xue Xue Bao Yi Xue Ban; 2019 Dec; 50(6):821-826. PubMed ID: 31880112
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Protein kinase Ciota is required for pancreatic cancer cell transformed growth and tumorigenesis.
    Scotti ML; Bamlet WR; Smyrk TC; Fields AP; Murray NR
    Cancer Res; 2010 Mar; 70(5):2064-74. PubMed ID: 20179210
    [TBL] [Abstract][Full Text] [Related]  

  • 7. YAP1 oncogene is a context-specific driver for pancreatic ductal adenocarcinoma.
    Tu B; Yao J; Ferri-Borgogno S; Zhao J; Chen S; Wang Q; Yan L; Zhou X; Zhu C; Bang S; Chang Q; Bristow CA; Kang Y; Zheng H; Wang H; Fleming JB; Kim M; Heffernan TP; Draetta GF; Pan D; Maitra A; Yao W; Gupta S; Ying H
    JCI Insight; 2019 Nov; 4(21):. PubMed ID: 31557131
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Ribonucleoprotein HNRNPA2B1 interacts with and regulates oncogenic KRAS in pancreatic ductal adenocarcinoma cells.
    Barceló C; Etchin J; Mansour MR; Sanda T; Ginesta MM; Sanchez-Arévalo Lobo VJ; Real FX; Capellà G; Estanyol JM; Jaumot M; Look AT; Agell N
    Gastroenterology; 2014 Oct; 147(4):882-892.e8. PubMed ID: 24998203
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Lunatic Fringe is a potent tumor suppressor in Kras-initiated pancreatic cancer.
    Zhang S; Chung WC; Xu K
    Oncogene; 2016 May; 35(19):2485-95. PubMed ID: 26279302
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Nicotine promotes initiation and progression of KRAS-induced pancreatic cancer via Gata6-dependent dedifferentiation of acinar cells in mice.
    Hermann PC; Sancho P; Cañamero M; Martinelli P; Madriles F; Michl P; Gress T; de Pascual R; Gandia L; Guerra C; Barbacid M; Wagner M; Vieira CR; Aicher A; Real FX; Sainz B; Heeschen C
    Gastroenterology; 2014 Nov; 147(5):1119-33.e4. PubMed ID: 25127677
    [TBL] [Abstract][Full Text] [Related]  

  • 11. CCAT2 is an oncogenic long non-coding RNA in pancreatic ductal adenocarcinoma.
    Cai Y; Li X; Shen P; Zhang D
    Biol Res; 2018 Jan; 51(1):1. PubMed ID: 29298720
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Oncogenic Kras-Mediated Cytokine CCL15 Regulates Pancreatic Cancer Cell Migration and Invasion through ROS.
    Messex JK; Adams KLA; Hawkins WG; DeNardo D; Bardeesy N; Billadeau DD; Liou GY
    Cancers (Basel); 2022 Apr; 14(9):. PubMed ID: 35565279
    [TBL] [Abstract][Full Text] [Related]  

  • 13.
    Inman KS; Liu Y; Scotti Buzhardt ML; Leitges M; Krishna M; Crawford HC; Fields AP; Murray NR
    Cancers (Basel); 2022 Feb; 14(3):. PubMed ID: 35159064
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Targeting the oncogenic protein kinase Ciota signalling pathway for the treatment of cancer.
    Fields AP; Frederick LA; Regala RP
    Biochem Soc Trans; 2007 Nov; 35(Pt 5):996-1000. PubMed ID: 17956262
    [TBL] [Abstract][Full Text] [Related]  

  • 15. COSMC knockdown mediated aberrant O-glycosylation promotes oncogenic properties in pancreatic cancer.
    Hofmann BT; Schlüter L; Lange P; Mercanoglu B; Ewald F; Fölster A; Picksak AS; Harder S; El Gammal AT; Grupp K; Güngör C; Drenckhan A; Schlüter H; Wagener C; Izbicki JR; Jücker M; Bockhorn M; Wolters-Eisfeld G
    Mol Cancer; 2015 May; 14():109. PubMed ID: 26021314
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The miR-217 microRNA functions as a potential tumor suppressor in pancreatic ductal adenocarcinoma by targeting KRAS.
    Zhao WG; Yu SN; Lu ZH; Ma YH; Gu YM; Chen J
    Carcinogenesis; 2010 Oct; 31(10):1726-33. PubMed ID: 20675343
    [TBL] [Abstract][Full Text] [Related]  

  • 17. A genetically engineered mouse model developing rapid progressive pancreatic ductal adenocarcinoma.
    Yamaguchi T; Ikehara S; Nakanishi H; Ikehara Y
    J Pathol; 2014 Oct; 234(2):228-38. PubMed ID: 25042889
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Inactivation of Smad4 accelerates Kras(G12D)-mediated pancreatic neoplasia.
    Kojima K; Vickers SM; Adsay NV; Jhala NC; Kim HG; Schoeb TR; Grizzle WE; Klug CA
    Cancer Res; 2007 Sep; 67(17):8121-30. PubMed ID: 17804724
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Oncogenic KRAS Targets MUC16/CA125 in Pancreatic Ductal Adenocarcinoma.
    Liang C; Qin Y; Zhang B; Ji S; Shi S; Xu W; Liu J; Xiang J; Liang D; Hu Q; Ni Q; Xu J; Yu X
    Mol Cancer Res; 2017 Feb; 15(2):201-212. PubMed ID: 28108627
    [TBL] [Abstract][Full Text] [Related]  

  • 20. EVI1 oncogene promotes KRAS pathway through suppression of microRNA-96 in pancreatic carcinogenesis.
    Tanaka M; Suzuki HI; Shibahara J; Kunita A; Isagawa T; Yoshimi A; Kurokawa M; Miyazono K; Aburatani H; Ishikawa S; Fukayama M
    Oncogene; 2014 May; 33(19):2454-63. PubMed ID: 23752186
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.